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Background: Primary plasma cell leukemia (pPCL) and
multiply-refractory multiple myeloma (MM) are plasma cell
dyscrasias with a median survival of <1 year without
aggressive treatment. Prolonged remission can be achieved
following allogeneic hematopoietic cell transplantation
(alloHCT) in this population, although survival may be
compromised by treatment-related mortality (TRM). With
the intention of providing long-term disease control, we
have offered a myeloablative conditioning regimen con-
taining melphalan 100 mg/m2 and 9 Gy of total body irra-
diation (MEL100/TBI9) followed by alloHCT to patients with
these diseases.
Methods: Seven patients with pPCL and 2 patients with
multiply-refractory MM underwent MEL100/TBI9 alloHCT at
the University of Pennsylvania between June 2009 and
January 2013. MEL was given as a single infusion of 100 mg/
m2 on day -3 and TBI as 150 cGy twice daily on days -2, -1
and 0. Paliferminwas given on days -4 (60 mg/kg) and 0 (180
mg/kg) for prevention of mucositis. Methotrexate and
tacrolimus were used for graft-versus-host-disease (GVHD)
prophylaxis. Therapies pre- and post-alloHCT were given at
the discretion of the treating physician.
Results: The median number of therapies pre- alloHCT was
3.5 (range 1-10) including bortezomib in 7 patients and high-
dose melphalan in 2 patients. Karnofsky Performance Status
pre- alloHCT was <80 in 4 patients. The median age at
alloHCT was 48 years (range 42-57). The donor source was aFigure I. EFS and OS based on disease respHLA-matched sibling in 5 patients and a 10/10 HLA-matched
unrelated donor in 4 patients. Disease response pre- alloHCT
was very good partial response (VGPR) or better for 4 pa-
tients, partial response (PR) for 3 patients and stable disease/
progressive disease (SD/PD) for 2 patients. Lenalidomide
maintenance was given post-alloHCT to 3 patients. Acute
GVHD of the intestine (3 patients; grade II, III and unknown)
and skin (1 patient; grade II) as well as chronic GVHD of the
oral cavity (2 patients; mild, moderate), skin (1 patient;
moderate) and eyes (1 patient; moderate) was observed.
With a median length of follow-up of 31.6 months post-
alloHCT (range 6.7-49.9) for patients surviving >100 days
(n¼6), the median event-free survival (EFS) was 28.2 months
and the median overall survival (OS) was not yet reached. As
shown in Figure I, patients achieving VGPR or better prior to
alloHCT experienced prolonged EFS and OS. TRM was expe-
rienced by 3 patients (2 with SD/PD and 1 with PR pre-
alloHCT), with all deaths occurring within approximately 30
days post-alloHCT due to sepsis.
Conclusions: In pPCL and multiply-refractory MM patients
demonstrating response to prior therapy, consolidation with
MEL100/TBI9 alloHCT can result in long-term survival
without severe toxicity. MEL100/TBI9 should be analyzed
prospectively either alone or in comparison to alternative
alloHCT conditioning regimens in this patient population.366
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Allogeneic hematopoietic cell transplantation (allo-HCT) can
be curative in many patients with intermediate and high risk
AML. However, patients with AMLwho relapse post allo-HCT
typically have a dismal prognosis with limited therapeutic
options. The activity and minimal toxicity associated with
hypomethylating agents (hypomeths) makes them poten-
tially useful in the management of post allo-HCT relapsed
AML patients. However, their use in this setting has not beenonse prior to MEL 100/TBI9 alloHCT
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underwent a ﬁrst allo-HCT for AML at our center during Feb.
2005 - May 2013. Patient characteristics were: median age,
53 (18-74); M¼75, F¼87; MRD¼59, MUD¼67, haplo¼36;
ablative conditioning¼98, RICT/NST¼64; PBSC¼142,
BM¼20; CIBMTR risk category- high¼53, intermediate¼28,
low¼74, unknown¼7. Post-relapse therapy (PRT) was
determined by the attending physician and patient prefer-
ence. Patient characteristics, PRT, GVHD and survival were
prospectively collected. With a median follow-up for sur-
viving patients of 22.4 months, relapse of AML post-allo-HCT
occurred in 55 patients (22 MRD, 24 MUD, 9 haplo; cytoge-
netic risk 23 poor, 31 intermediate, 1 unknown) at a median
of 113 days (25-1106) post allo-HCT. Thirty-four patients
(62%) were treated with a hypometh post-relapse (17 aza-
citidine, 10 decitabine, 7 both) (12 hypometh alone, 11
combined with chemotherapy, 11 sequentially with chemo-
therapy). Median number of hypometh cycles was 2 (1-9). Of
the 23 patients that received at least 2 hypometh cycles, 14
achieved CR or CRi. DLI was administered in 15 of the 55
relapsed patients and 16 patients received a second allo-HCT.
Estimated Kaplan-Meier probability of post-relapse survival
(PRS) at 6,12 and 24months for all patients was 53%, 36% and
19% and was not signiﬁcantly different for patients who
developed any versus no PRT GVHD. However, PRS at 6 and
12months was 62% (95% CI 43-76%) and 38% (95% CI 22-54%)
in patients who received post-relapse hypomeths versus 38%
(95% CI 18-58%) and 33% (95% CI 15-53%) in patients who did
not (p¼0.063 Gehan’s test). There was no difference in PRS at
24 months. PRS > 1 year was achieved in 19 of 55 patients (9
received a second allo-HCT, 9 received DLI, 12 received a
hypometh). At the time of writing, 6 patients are alive and in
CR at a median of 49 months (10-72) post-relapse. Of the 6
patients (5 MRD, 1 MUD; cytogenetic risk 2 poor, 4 inter-
mediate), 4 received hypomeths, 3 received a second trans-
plant, 1 received DLI, and 4 have active GVHD.
Relapse post allo-HCT remains a major obstacle to long-term
survival in patients with AML. The use of hypomeths may be
associated with a prolongation of early PRS although it does
not appear to increase PRS beyond one year. PRS beyond one
year can be achieved without a second allogeneic transplant
in a minority of relapsing patients. Combination of therapy
with hypomeths and novel agents may be necessary to
impact long-term outcome.367
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Combining a CD34+ selected haplo-graft with a full graft cord
blood (CB) unit is a cell support procedure that can make
single CB available as a donor source to a larger proportion ofpatients. Early haplo-donor cell engraftment may serve as a
myeloid bridge until sustainable CB-engraftment. In addition
it has been hypothesized that haplo-derived innate anti-tu-
mor activity (e.g. NK- / gd-Tcells through other cell selection
techniques) plus CB could be a platform for multi-modal
anti-tumor activity in high-risk malignancies. The latter in
the context of omitting serotherapy. The impact of sero-
therapy-exposure on the success of "haplo-myeloid bridge to
CB engraftment" is however unknown.
Methods: Since 2009 in the UMC Utrecht 2 haplo-CB pro-
tocols were open; 1) active infection and/or known difﬁcult
engraftment without a conventional donor available: CB +
CD34+selected Haplo-id donor (5milj CD34+/kg), 2) Poor risk
malignancies, not eligible to other treatment protocols: CB +
CD19/abTCR depleted haplo-id donor (5milj CD34+/kg).
Conditioning regimens: 1st HCT busulfan (targeted cum.ex-
posure of 90mg*h/L)+ Fludarabine (Flu)+ Thymoglobulin
(ATG) in protocol 1 or Flu/Cyclophosphamide (Cy)/TBI as RIC-
alternative; 2nd HCT Treosulfan, Flu+Campath (TreoFluCamp:
protocol 1). G-CSF was given from day +7. Patients received
GvHD-profylaxis with CsA and pred 1 mg/kg. Active-ATG
levels and Campath levels were measured as described pre-
viously (Jol et al. BMT 2012). The association of serotherapy-
exposure for the endpoints overall survival (OS), non-relapse
mortality (NRM), neutrophil recovery and graft failure (GF)
was analyzed. GF was deﬁned as either "early loss of Haplo
and no engraftment of the CB" or secondary loss of both
grafts. Logrank testing was used in statistical analyses.
Results: 22 patients were included (18 protocol 1; 4 protocol
2): 20 patients received FluBu (15 ATG, 1 Campath), 1 Treo-
FluCamp and 1 FluCyTBI. Median nucleated cell dose was 4.1
x 10e7/kg (2.0-20.0). There was a cumulative incidence (CI)
of neutrophil recovery of 81% with a median of 13 days. The
CI of GFwas however 4311%. Themedian "active ATG-AUC"
(area under the curve) was 17 IU*day/L (1 pat no Campath
AUC, 1 very high AUC: 150 IU*day/L). Patients were grouped
to having no serotherapy (n¼5), a low exposure (AUC<me-
dian: n¼8), or high exposure (AUC3 median: n¼9). GF were
signiﬁcantly higher in the no serotherapy/low AUC group
(p¼0.032: Fig 1) vs. the high AUC group. 3-yr prob. of OS was
48 12% (32 17% for the no/low AUC vs. 65  17% for high
AUC, p¼0.18 ). NRM in the no/low AUC group was 5616%
versus 2214% for high-AUC (Fig.2. p¼0.21).
In conclusion: A minimum of serotherapy exposure is
required for a successful "haplo-myeloid bridge to CB
engraftment". It is doubtful whether omitting serotherapy
will have a place in haplo-CB HCT. With sufﬁcient
